The patent protection period in India for semaglutide, the active ingredient in Ozempic developed by the Denmark-based healthcare company Novo Nordisk, has expired. Following this development, at least four major India-based pharmaceutical manufacturers have taken action to launch generic versions of the drug, which is highly sought after globally for the treatment of obesity and […]
